ARRY-382 and GW-2580, innovative highly selective inhibitors of CSF1R, have demonstrated good tolerance and safety in clinical phase studies in patients with advanced or metastatic tumors but their effect in brain tumors such as gliomas has not yet been evaluated [59,60]. The gene discussed is CSF1R; the disease is glioma.